Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
Authors
Keywords
-
Journal
Blood Advances
Volume 5, Issue 1, Pages 143-155
Publisher
American Society of Hematology
Online
2021-01-11
DOI
10.1182/bloodadvances.2020002732
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel
- (2020) Sattva S Neelapu et al. BLOOD
- Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma
- (2020) Tanaya Shree et al. JOURNAL OF CLINICAL ONCOLOGY
- Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
- (2020) Kitsada Wudhikarn et al. Blood Cancer Journal
- Early and late hematologic toxicity following CD19 CAR-T cells
- (2019) Shalev Fried et al. BONE MARROW TRANSPLANTATION
- Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
- (2019) Ana Cordeiro et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
- (2018) Gisa Ellrichmann et al. JOURNAL OF NEUROLOGY
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors
- (2016) Jo-Anne H. Young et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
- (2016) V. G. Bhoj et al. BLOOD
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000–2010
- (2016) Kate Buchacz et al. JOURNAL OF INFECTIOUS DISEASES
- Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma
- (2016) Kaori Ito et al. ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections
- (2011) Daniel Tesfa et al. ARTHRITIS AND RHEUMATISM
- The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls
- (2011) Brian T. Hill et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immune Recovery after Autologous Stem Cell Transplantation Is Not Different for HIV‐Infected versus HIV‐Uninfected Patients with Relapsed or Refractory Lymphoma
- (2010) Cecilia Simonelli et al. CLINICAL INFECTIOUS DISEASES
- The effect of Rituximab treatment on T cells
- (2010) C Diaz-Torné et al. Journal of Translational Medicine
- Immune recovery after fludarabine–cyclophosphamide–rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy
- (2010) L Ysebaert et al. LEUKEMIA
- Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma
- (2009) Y. L. Kasamon et al. ANNALS OF ONCOLOGY
- Good and bad memories following rituximab therapy
- (2009) E. William St.Clair ARTHRITIS AND RHEUMATISM
- Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma
- (2009) Timothy S. Fenske et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
- (2008) Ben De Pauw et al. CLINICAL INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started